ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Key facts

Sponsor

Canadian Cancer Trials Group

Principal Investigator

Amit Oza, MD

Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada

Intervention

Acetylsalicylic acid(drug)

Enrollment

117 enrolled

Eligibility

18 years · FEMALE

Timeline

2018 – 2026

Study locations (17)

• Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
• Prince of Wales Hospital, Randwick, New South Wales, Australia
• Westmead Hospital, Westmead, New South Wales, Australia
• Peter McCallum Cancer Institute, Melbourne, Victoria, Australia
• King Edward Memorial Hospital, Subiaco, Western Australia, Australia
• St John of God Subiaco, Subiaco, Western Australia, Australia
• Tom Baker Cancer Centre, Calgary, Alberta, Canada
• Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
• CancerCare Manitoba, Winnipeg, Manitoba, Canada
• Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
• Kingston Health Sciences Centre, Kingston, Ontario, Canada
• North York General Hospital, Toronto, Ontario, Canada
• Women's College Hospital, Toronto, Ontario, Canada
• CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada
• CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
• +2 more locations on ClinicalTrials.gov

Collaborators

Apotex Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Malignant epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07508306
  Patent Blue SLN in Early Ovarian Cancer Prospective Study (FIGO I-II) Evaluating Patent Blue SLN Mapping. Injection Into IP/UO Ligaments in Situ. Goals: Assess Feasibility and Accuracy vs Standard Lymphadenectomy to Minimize Surgical Morbidity
  Faculty of Medicine of Tunis
• RECRUITINGPHASE1NCT07524322
  Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  Regor Pharmaceuticals Inc.
• RECRUITINGPHASE1NCT06366490
  Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
  PhotonPharma, Inc.
• RECRUITINGPHASE1NCT07402915
  Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
  AstraZeneca
• RECRUITINGPHASE2NCT07158021
  Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial
  University of Michigan Rogel Cancer Center
• RECRUITINGNANCT07280312
  Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
  Mayo Clinic
• RECRUITINGPHASE2NCT06971744
  Autophagy Maintenance (AUTOMAIN)
  Medical University of South Carolina
• RECRUITINGPHASE3NCT06963268
  Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)
  Instituto de Investigacion Sanitaria La Fe

See all trials for Malignant epithelial tumor of ovary →